Subject Index

A
Acetylcholine receptor, neuronal muscarinic receptors and proliferation 22, 23
Activin A, induction of thyroid endoderm 33
N-cylphosphatidylethanolamine (NACE), food intake regulation 201, 202
Adenotonsillectomy childhood weight gain 141, 142
growth and growth biomarker changes 142, 143
Adipose tissue adipocyte turnover dynamics 135, 136
brown adipose tissue cold-activated tissue in healthy men 137, 18
functions in human adults 137
IGF1 autocrine action in adipocytes 56
white fat progenitor cells in vasculature 136, 137
Adrenarche, premature adrenarche and prepubertal growth acceleration 105, 106
Adrenocortical carcinoma inhibition by SF-1 inverse agonists 98
insulin-like growth factors
IGF1 therapeutic targeting 97
IGF2 and receptor expression 97
PKF115-584 inhibition 98
Aldosterone, hypertension, low birth weight, and programming 95
Androgen insensitivity syndrome, genotype-phenotype correlations 194
Androstenediol, urinary levels and prediction of diaphyseal bone strength in late puberty 106, 107
Angiotensin II blockade and aortic root dilation prevention in Marfan’s syndrome 202, 203
type 1 receptor disruption and longevity in mice 95, 96
Antipsychotic drugs, diabetes type II risks 158, 159
α1-Antitrypsin, treatment effects in diabetic mouse model 111, 112
APS-1, see Polycytemic syndrome type 1
Aquaporins, AQP1 and endocrine cell secretory granule biogenesis role 204
Arginine vasopressin osmotic and nonosmotic regulation during prolonged exercise 19, 20
receptor 1a gene variation and pair-bonding behavior in humans 216, 217
Autoimmune hypophysitis autoantigen discovery 23
T regulatory cells and types of disease 24, 25
Autophagy, regulation of lipid metabolism 200, 201

B
Bariatric surgery diabetes type II reversal in adolescents 157, 158
intestinal gluconeogenesis and early metabolic changes 140, 141
BDNF, see Brain-derived neurotrophic factor
Beckwith-Wiedemann syndrome (BWS), NLRP2 germline mutation 43, 44
Beta cell
diabetes type I 112, 113
Bisphosphonates, osteogenesis imperfecta effects in children 75, 76
BMD, see Bone mineral density
Bone mineral density (BMD) contraceptive effects in adolescent females 194, 195
diabetic young women 116
Brain-derived neurotrophic factor (BDNF), obesity role in WAGR syndrome 205, 206
Breast development, see Puberty
Brown adipose tissue, see Adipose tissue
BWS, see Beckwith-Wiedemann syndrome

C
Caffeine, pregnancy intake and fetal growth restriction 58, 59
CAH, see Congenital adrenal hyperplasia
Calcium-sensing receptor (CaSR), skeletal development role 65
CaSR, see Calcium-sensing receptor
CBX2, mutations in 46,XY karyotype 86
Celiac disease diabetes genetic similarities 128, 129
screening and long-term follow-up 222, 223
CGM, see Continuous glucose monitoring
Circadian clock, see Cryptochromes; Glucocorticoids; Liver circadian clock
CNP, see C-type natriuretic peptide
Congenital adrenal hyperplasia (CAH), see also 21-Hydroxylase deficiency dehydroepiandrosterone therapy effects in young women 103, 104
female fertility assessment in classical disease 101
glucocorticoid therapy 183, 184
gonadal function and pregnancy in woman with lipid congenital adrenal hyperplasia 102
Continuous glucose monitoring (CGM) 182, 183
cystic fibrosis 182, 183
diabetes type I 181, 182
Contraceptives
bone mineral density in adolescent females 194, 195
management in young people with disabilities 89
Corticotropin test, meta-analysis in hypothalamic-pituitary adrenal insufficiency 108
Cortisol, attractive male effects on female release 109
Crytochromes, CRY1 and CRY2 in sexual dimorphism of mouse liver metabolism 50, 51
C-type natriuretic peptide (CNP), skeletal dysplasia management 61, 62
Cushing’s disease
blood pressure in pediatric patients 98, 99
pasireotide treatment of pituitary-dependent disease 16
CYP2C19, activity effects in 21-hydroxylase deficiency 96
CYP3A4, activity effects in 21-hydroxylase deficiency 96
CYP11A1, mutation and late-onset adrenal insufficiency and hypospadias in 46,XY patient 107
CYP21A2, see 21-Hydroxylase deficiency
Cystic fibrosis, continuous glucose monitoring 182, 183
Diabetes type I
α1-antitrypsin treatment effects in mouse model 111, 112
autoimmune T cell death induction by tumor necrosis factor agonism 121, 122
basal bolus therapy at diagnosis of children 118, 119
beta cells
adult pancreatic exocrine cell reprogramming 112
cytotoxic T lymphocyte targeting 112, 113
bone mineral density in young women 116
celiac disease genetic similarities 128, 129
evidence-based medicine carbohydrate counting impact 190, 191
cognitive function 190
continuous glucose monitoring in intensive treatment 181, 182
etanercept treatment 185
nasal insulin in prevention 191, 192
fluoxetine effects 110, 111
gene-wide association studies diabetic nephropathy susceptibility 124, 125
risk loci 123, 124
glutamic acid decarboxylase therapy 119, 120
HbA1c variability and microvascular complication risks 117, 118
IFIH1 variants and protection 165, 166
incidence trends for children 207
innate immunity and intestinal microbiota in development 208
lipid and amino acid metabolism dysregulation before islet autoimmunity 209
liraglutide study in mice 126, 127
metabolic memory concept and complication prevention 127, 128
microsphere-based vaccine 122, 123
osteoprotegerin levels and outcomes 125, 126
PLX647 treatment effects in mouse model 115
thyroid hormone and risk reduction in rat model 129, 130
urinary proteomics 114, 115
Diabetes type II
adolescents and early indications of complications 154
antipsychotic drug risks 158, 159
bariatric surgery and reversal in adolescents 157, 158
cardiac abnormalities in girls with poor glycemic control 155
ectoenzyme nucleotide pyrophosphatase phosphodiesterase 1 polymorphism 177
evidence-based medicine 186
genotype score in prediction 176, 177
hyperlipidemia management 160
laughter benefits 162
maternal diabetes effects on offspring age of onset 150, 151
risks 149, 150
melatonin receptor polymorphisms and risk 147, 148
metformin effects obese adolescents with normal glucose tolerance 155, 156
polycystic ovarian syndrome in obese adolescents 156, 157
microalbuminuria prevalence in Canadian First Nation children 153, 154
pre-teen insulin resistance and outcomes 151
prediabetes risk factors 151, 152
DECIPHER, database features 166, 167
Dehydroepiandrosterone (DHEA), congenital adrenal hyperplasia treatment effects in young women 103, 104
DHEA, see Dehydroepiandrosterone
D
transcription factor 7-like 2 polymorphism and risk 149

Dicer
Dicer1 and male germline differentiation 90
knockout mice and female sterility 89

Dietary fat
hypothalamic neuron apoptosis induction 2, 3
maternal high-fat diet and fetal programming of obesity 1, 2
Dietary restriction, tumor response 222
DiGeorge syndrome, genetic compensation 178
Dioxin, maternal exposure and neonatal thyroid function 35, 36
DNA methylation, see Epigenetics
Dyslipidemia, see Hyperlipidemia

E
ectoenzyme nucleotide pyrophosphatase phosphodiesterase 1 (ENPP1), polymorphism in diabetes type II 177
ENPP1, see Ectoenzyme nucleotide pyrophosphatase phosphodiesterase 1
Enriched environment, transgenerational learning and memory study 213
Epigenetics
brain glucocorticoid receptor epigenetic regulation in child abuse 105
DNA methylation profiles in twins 214
nucleosomeal binding protein 1 promoter hypomethylation 217, 218
Silver-Russell syndrome subgroups 52, 53
Estrogen receptor
ERα knock-in mutation studies 82
loss of function mutation and bone effects 68, 69
male fertility role 82, 83
GPR30 role in ovariectomized mice 69
Estrogen, sex-steroid related gene polymorphisms and serum levels in men 174
Etanercept, diabetes type I treatment 185
Evidence-based medicine androgen insensitivity syndrome genotype-phenotype correlations 194
contraception and bone mineral density in adolescent females 194, 195
cystic fibrosis and continuous glucose monitoring 182, 183
diabetes type I carbohydrate counting impact 190, 191
cognitive function 190
continuous glucose monitoring in intensive treatment 181, 182
etanercept treatment 185
nasal insulin in prevention 191, 192
diabetes type II 186
glucocorticoid therapy for congenital adrenal hyperplasia 183, 184
growth hormone therapy dose dependence of height with deficiency 189, 190
without deficiency 188
familial short stature and dosing 189
Noonan syndrome 195
small for gestational age studies 192, 193
thyroid autoimmunity in schoolchildren 187, 188
thyroid hormone dosing in congenital hypothyroidism 196, 197

F
FGFs, see Fibroblast growth factors
Fibroblast growth factors (FGFs)
FGF8 in thyroid development 32
FGF21 inhibition of growth hormone signaling 203
Fluoxetine, diabetes type I hypoglycemia counterregulatory response effects 120, 121
FRA2a, thyroid development role 32, 33
FTO gene
body mass index heritability 134
inactivation and protection from obesity 134, 135
variant in obesity 133, 167, 170

G
GABAER, GPR54 signaling and inhibition of gonadotropin-releasing hormone neurons 9
GAD, see Glutamic acid decarboxylase
Gastric bypass, see Bariatric surgery
GCKR, see Glucokinase regulatory protein
Genetic causation, evolutionary perspective 212, 213
GH, see Growth hormone
Ghrelin, growth hormone-releasing hormone as receptor agonist 54
GHRH, see Growth hormone-releasing hormone
Glucocorticoids adrenal peripheral clock in rhythmic production 99, 100
brain receptor epigenetic regulation in child abuse 105
congenital adrenal hyperplasia management 183, 184
7-ketocholesterol modulation in adipocytes 218, 219
Glucokinase regulatory protein (GCKR), polymorphisms and fasting plasma glucose 175
Glucokinase, polymorphisms and fasting plasma glucose 175
Glutamic acid decarboxylase (GAD), diabetes type I management 119, 120
GnRH, see Gonadotropin-releasing hormone
Gonadotropin-releasing hormone (GnRH) analog therapy guidelines in children 88
GPR54 signaling and GABA-mediated inhibition of gonadotropin-releasing hormone neurons 9
GPR30, estrogen receptor role in ovariectomized mice 69
GPR54 kisspeptin activation and antagonist discovery 7, 8
molecular evolution in vertebrates 6, 7
signaling and GABAβ inhibition of gonadotropin-releasing hormone neurons 9
Graves’ disease, relapse prediction in children 39
Growth hormone (GH)
FGF21 inhibition of signaling 203
pulsatile secretion analysis 57, 58
receptor agonist-induced conformational change 47, 48
pegvistomant antagonism and pituitary gigantism treatment 51, 52
splicing fidelity and deficiency 45
therapy dose dependence of height with deficiency 189, 190
without deficiency 188
familial short stature and dosing 189
Noonan syndrome 195
small for gestational age studies 192, 193
Growth hormone-releasing hormone (GHRH), ghrelin receptor agonist 54

H
HbA1c, variability and microvascular complication risks in diabetes 117, 118
HBI-85, Prader-Willi syndrome and paternal deficiency 42, 43
Height
Finland birth cohort study of genetic determinants 171
genome-wide scans and meta analysis of determinants 41, 42
neurofibromin and growth regulation 49
pegvistomant and pituitary gigantism treatment 51, 52
premature adrenarche and prepubertal growth acceleration 105, 106
Hepatic steatosis, postreceptor insulin resistance 204
11β-HSD1, see 11β-Hydroxysteroid dehydrogenase type 1
21-Hydroxylase deficiency clinical and molecular characterization of women cohort 100, 101
CYP2C19 and CYP3A4 activity effects 96
fertility and pregnancy outcome 101, 102
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1), 7-ketocholesterol competition and glucocorticoid modulation in adipocytes 218, 219
Hyperlipidemia
laughter benefits 162
postreceptor insulin resistance 204
screening in childhood 161
spectrum and management in children 161, 162
treatment in diabetes type II 160
Hypertension
Cushing’s disease in pediatric patients 98, 99
low birth weight and programming 95
Hypogonadotropic hypogonadism
age at menarche and gene association studies 85
tachykinin neurokinin B mutations in familial disease 9, 10
Hypophosphatemia
rickets diagnosis based on etiology 76, 77
vitamin D receptor genotype in hypophosphatemic rickets 72
Hypophysitis, see Autoimmune hypophysitis
Hypothalamus
apoptosis induction by high-fat diet 2, 3
nuclear factor-κB levels and obesity 3
Hypothyroidism
congenital hypothyroidism and thyroid hormone management
high-dose treatment and long-term intellectual outcome 34
high versus low dose therapy 35
idiopathic subclinical disease natural course in children and adolescents 37

I
IFIH1, variants and diabetes type I protection 165, 166
IGFBPs, see Insulin-like growth factor binding proteins
IGFs, see Insulin-like growth factors
Insulin, see also Diabetes type I
basal bolus therapy at diabetes diagnosis of children 118, 119
intensive therapy in intensive care 199
nasal insulin in diabetes type I prevention 191, 192
postreceptor insulin resistance in dyslipidemia and hepatic steatosis 204
very-low-birthweight infant management 199, 200
Insulin-like growth factor binding proteins (IGFBPs)
IGFBP3 promoter polymorphism and clinical significance 46, 47
IGFBP4 inhibition of Wnt signaling 48
Insulin-like growth factors (IGFs)
IGF1
adrenocortical carcinoma therapeutic targeting 97
autocrine action in adipocytes 56
postnatal mouse growth study 55
IGF2
adrenocortical tumor expression 97
translocation breakpoint disruption in intrauterine growth retardation and diabetes 44, 45
receptors antibody characterization 53, 54
brain receptor functions in growth and lifespan control 56, 57
N-methyl-D-aspartate receptor and IGF1 signaling interactions 50
Intensive care, insulin therapy 199

K
KCNRG, autoantibodies in APS-1 223, 224
7-Ketocholesterol, glucocorticoid modulation in adipocytes 218, 219
Kisspeptins
GPR54
activation and antagonist discovery 7, 8
signaling and GABAB inhibition of gonadotropin-releasing hormone neurons 9
molecular evolution in vertebrates 6, 7
testicular degeneration induction by high doses of kisspeptin-54 8

Leptin
brain functional magnetic resonance imaging findings 140
valproic acid effects in children 159
LIN28B, genetic variation and puberty timing 90, 91
Liraglutide, effects in diabetic mice 126, 127
Liver circadian clock, physiological significance 204, 205

M
Magnetic resonance imaging (MRI) leptin and brain functional magnetic resonance imaging findings 140
pituitary stalk prenatal imaging 15
Marfan’s syndrome, angiotensin blockade and aortic root dilation prevention 202, 203
Maternal care, sexual maturation effects in female rat 11, 12
MeCP2, see Methyl-CpG binding protein 2
Melanocortin receptors MC4R mutations and obesity lifestyle intervention outcome effects in children 139, 140
overview 167
MRAP regulation 104
Melatonin receptor (MTNR1B), polymorphisms and diabetes type II risk 147, 148
Menarche age at menarche chromosome 6q21 sequence variants 172
gene association studies 172, 173
hypogonadotropic hypogonadism gene association studies 85
late menarche as osteoporosis risk factor 70
Methotrexate (MTX), chronic treatment effects on bone formation 72, 73
Methotrexate, see Methotrexate
N-Methyl-D-aspartate (NMDA) receptor, IGF1 signaling interactions 50
Methyl-CpG binding protein 2 (MeCP2) neuron deletion studies 4, 5
transcriptional regulation 4
Mitochondrial DNA, mutation rate and clock studies 220, 221
MRAP, regulation of melanocortin receptors 104
MRI, see Magnetic resonance imaging
MTNR1B, see Melatonin receptor
Mycoplasm genitalium, synthetic genome assembly 215

N
NACE, see N-Acylphosphatidyl-ethanolamine
Neurofibromin, growth regulation 49
Neurokinin B, see Tachykinin neurokinin B
NKK2.1, see Thyroid transcription factor-1
NLRP2, Beckwith-Wiedemann syndrome germline mutation 43, 44
NMDA receptor, see N-Methyl-D-aspartate receptor
Noonan syndrome, growth hormone therapy 195
NR5A1, mutations in ovarian insufficiency 87, 88
NSBP1, see Nucleosomeal binding protein 1
Nucleosomeal binding protein 1 (NSBP1), promoter hypomethylation 217, 218

O
Obesity adenotonsillectomy and childhood weight gain 141, 142
autophagy regulation of lipid metabolism 200, 201

Laughter, benefits in diabetes care 162
brain-derived neurotrophic factor role in WAGR syndrome 205, 206
FTO gene
body mass index heritability 134
inactivation and protection from obesity 134, 135
variant in obesity 133, 167, 170
gastric bypass, see Bariatric surgery
genetic association studies and neuronal influence 167
genome-wide association studies 168, 169
hypothalamic nuclear factor-κB levels 3
leptin and brain functional magnetic resonance imaging findings 140
maternal high-fat diet and fetal programming 1, 2
MC4R mutations and lifestyle interventions in children 139, 140
metformin effects in obese adolescents
normal glucose tolerance 155, 156
polycystic ovarian syndrome 156, 157
oral glucose tolerance test reproducibility in overweight children 152, 153
PCSK1 mutations 169, 170
pediatric treatment behavioral interventions 143
Endocrine Society clinical practice guidelines 143, 144
meta-analysis of trials 143
review 144
SIRT1 activation and protection against diet-induced metabolic disorders 138, 139
thyrotropin-releasing hormone receptor polymorphisms and lean body mass 173, 174
valproic acid effects in children 159
Oct4, pluripotent stem cell induction from fibroblasts 214
OGTT, see Oral glucose tolerance test
OI, see Osteogenesis imperfecta
ONH, see Optic nerve hypoplasia
Optic nerve hypoplasia (ONH), congenital hypopituitarism association 13
Oral glucose tolerance test (OGTT), reproducibility in overweight children 152, 153
Osteoblast, prolactin effects 64, 65
Osteogenesis imperfecta (OI), bisphosphonate effects in children 75, 76
Osteoporosis
late menarche as risk factor 70
oxytocin levels and management 62, 63
sclerostin antibody treatment in rat model of postmenopausal osteoporosis 71
stem cell interventions 74, 75
Osteoprotegerin, levels and diabetes type I outcomes 125, 126
OTX2
dominant negative mutation in combined pituitary hormone deficiency 17
loss of function mutation with anophthalmia, combined pituitary hormone deficiency, and pituitary defects 17-19
pituitary development role 16, 17
Ovary
offspring production from germline stem cell line 79, 80
transplantation in childhood cancer 79
Ovulation, laparoscopic observation 82
Oxytocinonce anabolic effects 63
osteoporosis levels and management 62, 63
PCSK1, obesity mutations 169, 170
Pegvistomant, pituitary gigantism treatment 51, 52
Perfluorinated chemicals, maternal levels and subfecundity 92
Phosphatidylinositol-3-kinase (PI3K), tumor activity and dietary restriction resistance 223
PI3K, see Phosphatidylinositol-3-kinase
Pituitary
cell cycle control of development and disease 22
expressed sequence tag identification of developmental genes 21
hypophysitis, see Autoimmune hypophysitis
OTX2
development role 16, 17
dominant negative mutation in combined pituitary hormone deficiency 17
loss of function mutation with anophthalmia, combined pituitary hormone deficiency, and pituitary defects 17-19
p21Cip/Kip inhibition of tumor growth 22
prenatal magnetic resonance imaging 15
PKF115-584, adrenocortical carcinoma inhibition 98
Subject Index

PLX647, treatment effects in diabetic mouse model 115
POA, see Preoptic area
Polycystic ovarian syndrome (PCOS), metformin effects in obese adolescents 156, 157
Polyendocrine syndrome type 1 (APS-1), KCNRG autoantibodies 223, 224
Prader-Willi syndrome (PWS), HBl-85 paternal deficiency 42, 43
Pregnancy

caffeine intake and fetal growth restriction 58, 59
diabetes type II risks in offspring
maternal diabetes and obesity 149, 150
maternal diabetes and age of onset 150, 151
gonadal function and pregnancy in woman with lipid congenital adrenal hyperplasia 102
high-fat diet and fetal programming 1, 2
maternal thyroid disease and perinatal outcomes 186, 187
Preoptic area (POA), developmental profiles of neuroendocrine gene expression in male rats 10, 11
Progesterone receptor, membrane receptors and non-genomic actions 79, 80
Prolactin, osteoblast effects 64, 65
Prostate cancer, screening and mortality studies 221, 222
Proteomics, urinary proteomics in diabetes and chronic kidney disease 114, 115
PTH, see Parathyroid hormone
Puberty, see also Menarche breast development and age trends 91
LIN28B genetic variation and puberty timing 90, 91
management in young people with disabilities 89

maternal care sexual maturation effects in female rat 11, 12
PAPSS2 mutations in premature pubarche 93, 94
PWS, see Prader-Willi syndrome
Pygmies, origins and genetic diversity in western central Africa 211

R

Rapamycin, treatment effects on bone growth 73, 74
Reproductive aging, female effects on males 85, 86
Rett syndrome, Methyl-CpG binding protein 2 inactivation 4
ROHHADNET, endocrine manifestations 14

S

Sclerostin, antibody treatment in rat model of postmenopausal osteoporosis 71
SF-1, see Steroidogenic factor-1
SGA, see Small for gestational age
SHH, see Sonic Hedgehog
Silver-Russell syndrome (SRS), epigenetic subgroups 52, 53
SIRT1, activation and protection against diet-induced metabolic disorders 138, 139
Six3, regulation of forebrain Sonic Hedgehog enhancer 5, 6
Small for gestational age (SGA), growth hormone therapy studies 192, 193
Somatotroph early postnatal nutrition effects on function 25, 26
neuronal muscarinic acetylcholine receptors and proliferation 22, 23
Sonic Hedgehog (SHH), regulation of forebrain enhancer by Six3 5, 6
Sox2, pluripotent stem cell induction from fibroblasts 214
Speciation, sensory drive in cichlid fish 214
Spermatogonia, long-term survival in cryopreserved and xenografted testicular tissue 80, 81
SRS, see Silver-Russell syndrome
Stat3, respiration role in mitochondria 212
Stature, see Height
Stem cell
offspring production from ovary stem cell line 79, 80
osteoporosis interventions 74, 75
pluripotent stem cell induction adenoviral reprogramming 219
disease-specific cells 220
Oct4 and Sox2 214
Steroidogenic factor-1 (SF-1), central nervous system-specific knockout mice 25

T

TAC3, see Tachykinin neurokinin B
Tachykinin neurokinin B (TAC3), mutations in familial hypogonadotropic hypogonadism 9, 10
TCF7L2, see Transcription factor 7-like 2
Temperature, regulation of limb length in homeotherms 59, 60
Testicular degeneration, induction by high doses of kisspeptin-54 8
Testosterone
adult social behavior programming 84
attractive male effects on female release 109
Thyroid
autoimmunity in school-children 187, 188
development pathways activin A induction of thyroid endoderm 33
ERK2 role 32
FRS2a role 32, 33
<table>
<thead>
<tr>
<th>Page</th>
<th>Subject</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td>overview</td>
</tr>
<tr>
<td>32</td>
<td>Tbx1-Fgf8 pathway</td>
</tr>
<tr>
<td>35, 36</td>
<td>dioxin maternal exposure and neonatal thyroid function</td>
</tr>
<tr>
<td>39</td>
<td>Graves’ disease relapse prediction in children</td>
</tr>
<tr>
<td>37, 38</td>
<td>natural history of abnormal tests over 5 years in children</td>
</tr>
<tr>
<td>30</td>
<td>Thyroid cancer papillary microcarcinoma features</td>
</tr>
<tr>
<td>28, 29</td>
<td>thyroid transcription factor-1 mutation</td>
</tr>
<tr>
<td>29</td>
<td>ultrasound screening of childhood cancer survivors</td>
</tr>
<tr>
<td>27, 28</td>
<td>variants at 9q22.33 and 14q13.3</td>
</tr>
<tr>
<td>35</td>
<td>Thyroid hormone congenital hypothyroidism management high versus low dose therapy</td>
</tr>
<tr>
<td>34</td>
<td>high-dose treatment and long-term intellectual outcome</td>
</tr>
<tr>
<td>36, 37</td>
<td>diabetes type I risk reduction in rat model</td>
</tr>
<tr>
<td>38</td>
<td>Vitamin D deficiency treatment in children and toddlers</td>
</tr>
<tr>
<td>39</td>
<td>Thyrotropin-releasing hormone receptor (TRHR), polymorphisms and lean body mass</td>
</tr>
<tr>
<td>228, 29</td>
<td>Thyroid transcription factor-1 (NKX2.1; TTF-1), mutation in multinodular goiter and papillary thyroid carcinoma</td>
</tr>
<tr>
<td>38, 39</td>
<td>Thyrotrpin, levels and longevity</td>
</tr>
<tr>
<td>173, 174</td>
<td>Thyrotrpin-releasing hormone receptor (TRHR), polymorphisms and lean body mass</td>
</tr>
<tr>
<td>149</td>
<td>Transcription factor 7-like 2 (TCF7L2), polymorphism and diabetes type II risk</td>
</tr>
<tr>
<td>196, 197</td>
<td>Tyrosine kinase inhibitors, see PLX647</td>
</tr>
<tr>
<td>35</td>
<td>TRHR, see Thyrotrpin-releasing hormone receptor</td>
</tr>
<tr>
<td>34</td>
<td>TTF-1, see Thyroid transcription factor-1</td>
</tr>
<tr>
<td>48</td>
<td>Wnt, IGFBP4 inhibition of signaling</td>
</tr>
<tr>
<td>79</td>
<td>Ultrasoundography, thyroid cancer screening in childhood cancer survivors</td>
</tr>
<tr>
<td>72</td>
<td>Uterus, transplantation in childhood cancer</td>
</tr>
<tr>
<td>159</td>
<td>Valproic acid, obesity and leptin effects in children</td>
</tr>
<tr>
<td>173, 174</td>
<td>Vasopressin, see Arginine vasopressin</td>
</tr>
<tr>
<td>199, 200</td>
<td>Very-low-birthweight infant, insulin therapy</td>
</tr>
<tr>
<td>67, 68</td>
<td>Vitamin D receptor genotype in hypophosphatemic rickets</td>
</tr>
<tr>
<td>205, 206</td>
<td>WAGR syndrome</td>
</tr>
<tr>
<td>48</td>
<td>Wnt, IGFBP4 inhibition of signaling</td>
</tr>
</tbody>
</table>